CRDL•Cardiol Therapeutics reported a three-month net loss of CAD 13.32 million, up 34% year over year. Operating cash use for nine months fell 12% to CAD 16.47 million, cash rose to CAD 29.23 million, and the company later raised USD 4.55 million through its at-the-market offering.
Cardiol Therapeutics’ net loss widened 34% year over year to CAD 13.32 million for the three months ended September 30, 2026. Net cash used in operating activities fell 12% to CAD 16.47 million for the nine months ended September 30, while cash and cash equivalents rose 36% from December 31, 2025, to CAD 29.23 million. After the quarter ended, the company raised USD 4.55 million in gross proceeds under its 2026 at-the-market offering program.
